4/1/2010

ArQule's lung cancer drug ARQ 197 helped improve progression-free survival by 66% in patients with advanced, refractory nonsmall-cell lung cancer when combined with a similar treatment, erlotinib. The result puts ArQule on track to move on with late-stage development.

Full Story:
Reuters

Related Summaries